Daniel Rosas 🩸🦀

What actually happens when two oncologists disagree on stage? @DocOncMD gives a preview in this audio clip! Listen as he shares why the debate format hits differently and why these conversations matter once you’re back in clinic. We’re live this Saturday in Miami and you should join us: hubs.ly/Q046t2Lv0 #OLNGreatDebates #Oncology #MedicalOncology #CancerCare

Florida is showing up in a big way for #OLNGreatDebates this March in Miami! We’re proud to welcome an exceptional group of faculty from across the state, representing @MoffittNews, @SylvesterCancer, @MayoClinic, Memorial Cancer Institute, @AdventHealth, @MountSinaiMiami, @OncologyInst, and @MiamiCancerInst. Take a look at their debates: hmpglobalevents.com/olngreatdebates #Oncology #MedicalOncology #GICancer #LungCancer #BreastCancer #GUCancer #GynecologicOncology

@allisonoconn Some oncogene driven NSCLC

Today I learned immunotherapy is so effective for melanoma brain mets (same efficacy as peripherally) that if asymptomatic, treatment is immunotherapy, not radiation. Radiation is used if immunotherapy doesn’t work. Any other types of brain mets where systemic tx is preferred?

I am stepping out at the 2026 GO2 Hollywood 5K Walk/Run & Kite Fly. Join me or donate to help increase #LungCancer survival! do.nr/vo06r0oc via @DonorDrive

Fight For Air Climb - Miami Consider helping w my fundraiser, thanks a ton action.lung.org/site/TR;jsessi…

We are two dedicated HemOnc fellows looking for the next step in our careers. We are seeking two positions within the same geographic area in the USA and are beyond excited to start this new chapter! @e_toro123 #HemOnc #MedicalRecruitment #OncologyJobs #HematologyJobs

@FIFACentro @grok did he really say this?

🚨🗣️Mbappe : “We don’t celebrate little trophies like Supercopa, we celebrate when we win Champions League trophies. They don’t know what UCl finals feels like…”

Why do US medical residents typically earn $16 per hour?

Christmas came early this year 🎅 🎄

Latino gang representing 🇨🇴 🇺🇸 Proud and honored! #2025ASHAwards #ASH25 #ASHEducation #ASHTrainee #ASHTraineeCouncil @ASH_hematology @e_toro123 @DocOncMD @AEDiazMD @cvelezmejia

⁦@LuisRaezMD⁩ ⁦@Latinamd⁩ It has been a great pleasure to speak ⁦@OncLive⁩ during the #lungcancerawarenessmonth

Speaking tonight in Ft Lauderdale @OncLive #SOSS Lung Cancer with Chair @LuisRaezMD @DocOncMD @mhshospital @NaglaAKarimMD @GWtweets Dr Alberto Chiappori @MoffittNews #lcsm #LCAM @SylvesterCancer

@GeronimoMorgans Spot on. His evolution as an 8/6 hybrid is huge—tempo control through constant scanning/open body shape, breaking the first line early rather than over-carrying. And in OOP he locks rest-defence, seals half-spaces, sweeps second balls, wins duels. Deserves more flowers.

Plenty of deserved praise has gone Doku’s way for his remarkable improvement this season, yet Nico G has followed a similarly impressive trajectory in midfield. He’s been bossing every game he steps into and stats don't lie: circulating possession (controlling/dictating rhythm), dominating duels, passing first > carrying when deep and staying composed both IP & OOP. There aren’t enough flowers being given to him for the consistency and class he’s shown.

@GeronimoMorgans Couldn’t agree more with number 2

Winning is the philosophy of Manchester City. Winning at any cost is now the identity of this team. However, there are two pressing issues Pep Lijnders must address immediately: 1. Lack of intensity: We are not aggressive enough in our press, which gives opponents too much space and leaves us vulnerable to counters. 2. Poor coordination: Our pressing triggers and defensive shape are often disconnected, creating exploitable gaps. The second-half performance was strong because we dueled, we fought, and we showed spirit. But that level of commitment and cohesion must be consistent across both halves, in every game. It’s as simple as that.

@DouglasAdlerMD @dgermain21 Super helpful perspective. Posts like this make you stop and think about where you want your career to go

I was in academics for 20 years, and was a full Professor of Medicine with Tenure. 5 years ago I left for a large private GI group. People often ask me about pros and cons of both worlds. Here are my top tips to consider. #gitwitter #medtwitter #MedX

Nos complace anunciarles uno de nuestros eventos más importantes del año: un foro en línea, gratuito e interactivo sobre cáncer de pulmón. Este evento está diseñado específicamente para pacientes, familiares (cuidadores) y sobrevivientes de cáncer de pulmón. Detalles del Evento: ➡ Fecha: Sábado, 9 de agosto de 2025 ➡ Modalidad: En línea ➡ Costo: Gratuito ➡ Oportunidad única: Tendrá la posibilidad de interactuar y hacer preguntas directamente a médicos especialistas. No pierda esta oportunidad de obtener información valiosa y conectarse con expertos en el campo. Regístate gratis aquí give.cancergrace.org/event/foro-de-…

¿Estás interesado en aprender más sobre las Terapias Dirigidas de Cáncer de Pulmón en Español? Acompáñanos para una sesión informativa con el Dr. Rosas, fellow en Hematología y Oncología médica. El Dr. Rosas, egresado de la Universidad CES en Medellín, Colombia, completó su residencia en medicina interna en la Universidad de Texas San Antonio y se encuentra finalizando su entrenamiento en el Memorial Cancer Instituto en Florida. Su experiencia lo convierte en una voz experta para discutir los avances en el tratamiento del cáncer de pulmón. ¡No pierdas esta oportunidad de informarte y resolver tus dudas! Regístrate gratis aquí: cancergrace.org #CáncerDePulmon #TerapiasDirigidas #Salud #Oncología #DrRosas #EducaciónEnSalud

@LSOM_HemOnc @mazo_md @AEDiazMD @mayscancer @UTHSAResearch @DrSAHaddad Very lucky fellows!

Welcome to our first-year hem/onc fellows! Day #1 on the hematology and oncology inpatient services with our amazing attendings @mazo_md and @AEDiazMD ! @mayscancer @UTHSAResearch @DrSAHaddad

#ASCODirectPR this morning starts w @DocOncMD Dr Daniel Rosas @mhshospital reviewing advances in #SCLC #ASCO25 🔹#IMForte- atezolizumab +lurbi maintenance ES-SCLC : 3 mo OS w extra AEs 🔹#DeLLPhi304- tarlatamab vs. chemo in 2+line: new standard 🔹Alveltamig (trispecific T cell engaged) PhII ORR 62% #lcsm @TotalHealthConf

@SuyogCancer Hi dr Akhade, i would like to join

🌍📚 Calling the global oncology community! We've launched a WhatsApp Academic Group to share: 🔹 Key trial data 🔹 Conference updates 🔹 Oncology posts from X & LinkedIn 🔹 Article links 🔹 Tough case discussions (esp. where no MTB access) Ideal for oncology fellows & practicing oncologists — from LMICs and HICs. 📩 DM me with your mobile number to join. Let’s learn together! #OncoTwitter #MedEd #GlobalOncology